Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials

Caroline Piette,Stefan Suciu,E Clappier,Yves Bertrand,Séverine Drunat,Sandrine Girard,Karima Yacouben,Geneviève Plat,Nicole Dastugue,Françoise Mazingue,Nathalie Grardel,N. Van Roy,Anne Uyttebroeck,Costa,Odile Minckes,Nicolas Sirvent,Pauline Simon,Patrick Lutz,A. Ferster,Claire Pluchart,Maryline Poiree,Claire Freycon,Marie-Françoise Dresse,Frédéric Millot,Christophe Chantrain,J. van der Werff ten Bosch,K. Norga,C. Gilotay,Pierre-Simon Rohrlich,Yves Benoit,Hélène Cavé

Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials

2018

Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials

Keywords:

Cancer
Dexamethasone
RUNX1
Lymphoblastic leukaemia
Randomized controlled trial
Cancer research
ETV6
Biology
B cell
etv6 runx1
differential impact

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations